Vestal Point Capital LP Raises Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Vestal Point Capital LP lifted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 50.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,725,000 shares of the company’s stock after purchasing an additional 575,000 shares during the quarter. Structure Therapeutics comprises about 2.8% of Vestal Point Capital LP’s portfolio, making the stock its 11th biggest position. Vestal Point Capital LP’s holdings in Structure Therapeutics were worth $46,782,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd grew its stake in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after acquiring an additional 553 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after purchasing an additional 455 shares in the last quarter. Assetmark Inc. grew its position in Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock worth $62,000 after purchasing an additional 953 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company’s stock valued at $111,000 after purchasing an additional 3,549 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new position in Structure Therapeutics during the 4th quarter valued at approximately $113,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $25.17 on Monday. The firm’s fifty day moving average is $21.19 and its two-hundred day moving average is $26.37. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -34.01 and a beta of -1.69. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). As a group, equities research analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Citigroup began coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a “buy” rating and a $60.00 price target on the stock. Finally, HC Wainwright reduced their price objective on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, May 12th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.